Samsung Ventures, a key player in the life sciences sector, has made a strategic investment in BrickBio, Inc., a preclinical-stage biopharmaceutical company specializing in precision biologics. The investment, facilitated through the Samsung Life Science Fund and managed by Samsung Ventures, underscores Samsung's commitment to advancing innovative therapies to address unmet medical needs.

BrickBio is at the forefront of protein engineering technology, leveraging an expanded genetic code to develop advanced molecules and therapies, particularly in the field of antibody-drug conjugates (ADCs). This collaboration marks a significant milestone in Samsung's pursuit of novel biopharmaceutical solutions, with a focus on leveraging BrickBio's proprietary technology to explore new modalities such as AAV gene therapy.

"We are thrilled to partner with BrickBio to harness the power of protein engineering technology for the development of precision biologics," said Ho Sung Cho, Executive Vice President and Head of Early Research and Development at Samsung Bioepis. "By combining Samsung's expertise in biologics with BrickBio's innovative platform, we aim to accelerate the discovery and development of next-generation therapies to address a wide range of diseases."

BrickBio's technology enables the incorporation of synthetic amino acids into proteins, expanding the repertoire of molecular tools available for therapeutic intervention. This capability holds promise for creating novel therapeutics with enhanced precision and efficacy, offering new treatment options for patients with challenging medical conditions.

John Boyce, CEO and Co-Founder of BrickBio and Tiger Gene, expressed gratitude for Samsung's support and emphasized the potential of their protein engineering technology to drive therapeutic innovation. "This investment will fuel our efforts to advance our ADC candidates towards clinical development and further expand our pipeline of precision biologics," said Boyce.

The partnership between Samsung and BrickBio exemplifies a shared commitment to innovation and transformative healthcare solutions. Through collaborative research and development efforts, the companies aim to accelerate the translation of scientific discoveries into impactful therapies that address the evolving needs of patients worldwide.